The reactivity of β-lactams, the mechanism of catalysis and the inhibition of β-lactamases

Michael I. Page

Research output: Contribution to journalReview article

39 Citations (Scopus)

Abstract

Four membered β-lactam rings do not show unusual reactivity compared with their acyclic amide analogues and there is no evidence of concerted mechanisms for nucleophilic substitution reactions at the carbonyl centre. The identity of the general base/acid catalyst in the serine β-lactamases, which catalyse the hydrolysis of β-lactams, is unknown. There are no ideal transition state analogue inhibitors for these enzymes which involve several intermediates and transition states. The class C serine β-lactamase enhances the rate of phosphonylation of its active site serine residue by a similar magnitude to the enzyme rate enhancement factor for the hydrolysis of β- lactams. Comparisons are made between the stereochemical consequences of tetrahedral and trigonal bipyramidal intermediates for hydrolysis and phosphonylation respectively. Class B zinc β-lactamases are inhibited by thiol dipeptides with a D configuration at the cysteine centre analogous to the L configuration at C6 in penicillins. The mechanism of hydrolysis catalysed by the metallo-β-lactamases probably involves a di-anionic tetrahedral intermediate stabilised by zinc(II).

LanguageEnglish
Pages895-913
Number of pages19
JournalCurrent Pharmaceutical Design
Volume5
Issue number11
Publication statusPublished - 1 Nov 1999

Fingerprint

beta-Lactams
beta-Lactamases
Catalysis
Hydrolysis
Serine
Zinc
Dipeptides
Enzyme Inhibitors
Amides
Penicillins
Cysteine
Catalytic Domain
Acids
Enzymes

Cite this

@article{113dff351f8e4d7583a9d954a44a72d3,
title = "The reactivity of β-lactams, the mechanism of catalysis and the inhibition of β-lactamases",
abstract = "Four membered β-lactam rings do not show unusual reactivity compared with their acyclic amide analogues and there is no evidence of concerted mechanisms for nucleophilic substitution reactions at the carbonyl centre. The identity of the general base/acid catalyst in the serine β-lactamases, which catalyse the hydrolysis of β-lactams, is unknown. There are no ideal transition state analogue inhibitors for these enzymes which involve several intermediates and transition states. The class C serine β-lactamase enhances the rate of phosphonylation of its active site serine residue by a similar magnitude to the enzyme rate enhancement factor for the hydrolysis of β- lactams. Comparisons are made between the stereochemical consequences of tetrahedral and trigonal bipyramidal intermediates for hydrolysis and phosphonylation respectively. Class B zinc β-lactamases are inhibited by thiol dipeptides with a D configuration at the cysteine centre analogous to the L configuration at C6 in penicillins. The mechanism of hydrolysis catalysed by the metallo-β-lactamases probably involves a di-anionic tetrahedral intermediate stabilised by zinc(II).",
author = "Page, {Michael I.}",
year = "1999",
month = "11",
day = "1",
language = "English",
volume = "5",
pages = "895--913",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "11",

}

The reactivity of β-lactams, the mechanism of catalysis and the inhibition of β-lactamases. / Page, Michael I.

In: Current Pharmaceutical Design, Vol. 5, No. 11, 01.11.1999, p. 895-913.

Research output: Contribution to journalReview article

TY - JOUR

T1 - The reactivity of β-lactams, the mechanism of catalysis and the inhibition of β-lactamases

AU - Page, Michael I.

PY - 1999/11/1

Y1 - 1999/11/1

N2 - Four membered β-lactam rings do not show unusual reactivity compared with their acyclic amide analogues and there is no evidence of concerted mechanisms for nucleophilic substitution reactions at the carbonyl centre. The identity of the general base/acid catalyst in the serine β-lactamases, which catalyse the hydrolysis of β-lactams, is unknown. There are no ideal transition state analogue inhibitors for these enzymes which involve several intermediates and transition states. The class C serine β-lactamase enhances the rate of phosphonylation of its active site serine residue by a similar magnitude to the enzyme rate enhancement factor for the hydrolysis of β- lactams. Comparisons are made between the stereochemical consequences of tetrahedral and trigonal bipyramidal intermediates for hydrolysis and phosphonylation respectively. Class B zinc β-lactamases are inhibited by thiol dipeptides with a D configuration at the cysteine centre analogous to the L configuration at C6 in penicillins. The mechanism of hydrolysis catalysed by the metallo-β-lactamases probably involves a di-anionic tetrahedral intermediate stabilised by zinc(II).

AB - Four membered β-lactam rings do not show unusual reactivity compared with their acyclic amide analogues and there is no evidence of concerted mechanisms for nucleophilic substitution reactions at the carbonyl centre. The identity of the general base/acid catalyst in the serine β-lactamases, which catalyse the hydrolysis of β-lactams, is unknown. There are no ideal transition state analogue inhibitors for these enzymes which involve several intermediates and transition states. The class C serine β-lactamase enhances the rate of phosphonylation of its active site serine residue by a similar magnitude to the enzyme rate enhancement factor for the hydrolysis of β- lactams. Comparisons are made between the stereochemical consequences of tetrahedral and trigonal bipyramidal intermediates for hydrolysis and phosphonylation respectively. Class B zinc β-lactamases are inhibited by thiol dipeptides with a D configuration at the cysteine centre analogous to the L configuration at C6 in penicillins. The mechanism of hydrolysis catalysed by the metallo-β-lactamases probably involves a di-anionic tetrahedral intermediate stabilised by zinc(II).

UR - http://www.scopus.com/inward/record.url?scp=0032698787&partnerID=8YFLogxK

M3 - Review article

VL - 5

SP - 895

EP - 913

JO - Current Pharmaceutical Design

T2 - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 11

ER -